The AGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View AGEN Detailed Price Forecast - CNN Money | View AGEN Detailed Summary - Google Finance | ||
View AGEN Detailed Summary - Yahoo! Finance | View AGEN Stock Research & Analysis - Zacks.com |
View AGEN Trends & Analysis - Trade-Ideas | View AGEN Major Holders - Barrons | ||
View AGEN Call Transcripts - NASDAQ | View AGEN Breaking News & Analysis - Seeking Alpha | ||
View AGEN Annual Report - CompanySpotlight.com | View AGEN OTC Short Report - OTCShortReport.com | ||
View AGEN Fundamentals - TradeKing | View AGEN SEC Filings - Bar Chart | ||
View Historical Prices for AGEN - The WSJ | View Performance/Total Return for AGEN - Morningstar | ||
View the Analyst Estimates for AGEN - MarketWatch | View the Earnings History for AGEN - CNBC | ||
View the AGEN Earnings - StockMarketWatch | View AGEN Buy or Sell Recommendations - MacroAxis | ||
View the AGEN Bullish Patterns - American Bulls | View AGEN Short Pain Metrics - ShortPainBot.com |
View AGEN Stock Mentions - StockTwits | View AGEN Stock Mentions - PennyStockTweets | ||
View AGEN Stock Mentions - Twitter | View AGEN Investment Forum News - Investor Hub | ||
View AGEN Stock Mentions - Yahoo! Message Board | View AGEN Stock Mentions - Seeking Alpha |
View Insider Transactions for AGEN - SECform4.com | View Insider Transactions for AGEN - Insider Cow | ||
View AGEN Major Holdings Summary - CNBC | View Insider Disclosure for AGEN - OTC Markets | ||
View Insider Transactions for AGEN - Yahoo! Finance | View Institutional Holdings for AGEN - NASDAQ |
View AGEN Stock Insight & Charts - FinViz.com | View AGEN Investment Charts - StockCharts.com | ||
View AGEN Stock Overview & Charts - BarChart | View AGEN User Generated Charts - Trading View |
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Posted on Wednesday April 24, 2024
LEXINGTON, Mass., April 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab ("BOT/BAL") in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be held
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Posted on Tuesday April 23, 2024
LEXINGTON, Mass., April 23, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
Posted on Monday April 22, 2024
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Posted on Friday April 12, 2024
LEXINGTON, Mass., April 12, 2024--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' bro